In multifocal atrial tachycardia, which class of agents is considered the treatment of choice?

In multifocal atrial tachycardia, which class of agents is considered the treatment of choice?

• A. Calcium channel blockers
• B. Beta blockers
• C. Digoxin
• D. Amiodarone

Answer: (A)

In multifocal atrial tachycardia, the goal is to slow the rapid ventricular response by reducing AV nodal conduction while you address underlying causes like hypoxemia or COPD. Non-dihydropyridine calcium channel blockers, such as verapamil or diltiazem, are the treatment of choice because they effectively decrease AV nodal conduction and lower the ventricular rate without relying on the atrial rhythm, which is coming from multiple foci. Beta blockers could also slow AV conduction but are less favorable here due to the frequent coexistence of COPD and potential bronchospasm. Digoxin isn’t reliably effective in MAT because the atrial impulses originate from several foci, making rate control via the AV node insufficient. Amiodarone may be considered if first-line measures fail or if the patient is unstable, but it’s not the preferred initial therapy.

In multifocal atrial tachycardia, the goal is to slow the rapid ventricular response by reducing AV nodal conduction while you address underlying causes like hypoxemia or COPD. Non-dihydropyridine calcium channel blockers, such as verapamil or diltiazem, are the treatment of choice because they effectively decrease AV nodal conduction and lower the ventricular rate without relying on the atrial rhythm, which is coming from multiple foci. Beta blockers could also slow AV conduction but are less favorable here due to the frequent coexistence of COPD and potential bronchospasm. Digoxin isn’t reliably effective in MAT because the atrial impulses originate from several foci, making rate control via the AV node insufficient. Amiodarone may be considered if first-line measures fail or if the patient is unstable, but it’s not the preferred initial therapy.